Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Active:	Yes
Cancer Type:	Prostate Cancer	NCT ID:	NCT04221542
Trial Phases:	Phase I	Protocol IDs:	20180146 (primary) NCI-2020-00424 2021-005052-11 2023-504361-23
Eligibility:	18 Years and older, Male	Study Type:	Treatment
Study Sponsor:	Amgen, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04221542

Summary

The overall aim of the trial is to evaluate the safety, tolerability, and
pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate
and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09
July 2025), only Parts 4A expansion, 6, and 7 are open to accrual.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.